[A comparison for the patency rate of TASC II C/D femoropopliteal arterial disease between endovascular treatment and arterial bypass therapy].
To compare the long term outcome of The Trans-Atlantic Inter-Society Consensus (TASC) II C/D femoropopliteal arterial disease between endovascular treatment and arterial bypass therapy. A retrospective study was undertaken on 92 patients (97 limbs) receiving endovascular treatment and graft bypass therapy for TASC II C/D femoropopliteal arterial disease from January 2009 to January 2014, 58 male and 34 female. Mean age was (68±9) years (range, 56 years to 86 years), 52 patients over 70 years old (occupied 56.5%). Severe intermittent claudication, rest pain, minor tissue defect and foot ulceration or gangrene were in 51 limbs, 33 limbs, 10 limbs and 3 limbs, respectively. Technical success rate, perioperative complication rate, mortality rate, patency rate and limb salvage rate, ankle brachial index (ABI) were evaluated. Technical success rate of endovascular treatment was 96.0%, severe complication rate was 8.6%. No death cases at perioperative period, preoperative ABI was (0.40±0.16), postoperative ABI increase to (0.72±0.24). Technical success rate of graft bypass therapy was 95.4%, severe complication rate was 15.9%, perioperative mortality rate was 4.5%, preoperative ABI was (0.36±0.19), postoperative ABI increase to (0.76±0.21). Primary term patency rate, cumulative patency rate and cumulative limb salvage rate at 24 months of endovascular treatment were 67.4%, 79.0% and 93.0% respectively. Graft bypass therapy were 71.4%, 79.4% and 92.3% respectively. Endovascular treatment of TASC II C/D femoropopliteal arterial disease has the same patency rate and limb salvage rate to graft bypass therapy, lesions is microinvasive, safe and effective.